Acurx Pharmaceuticals, Inc. Research and Development Expense
Acurx Pharmaceuticals, Inc. (ACXP) reported Research and Development Expense of $1.07 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Acurx Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-06-30 was $1.07M, a 104.41% increase year-over-year.
- Acurx Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-03-31 was $341.47K, a 42.97% decline year-over-year.
- Acurx Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-12-31 was $281.81K, a 65.84% decline year-over-year.
- Acurx Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-09-30 was $429.69K, a 64.14% decline year-over-year.
- Acurx Pharmaceuticals, Inc. research and development expense for fiscal 2025 was $1.83M, a 66.05% decline from fiscal 2024.
- Acurx Pharmaceuticals, Inc. research and development expense for fiscal 2024 was $5.40M, a 10.59% decline from fiscal 2023.
- Acurx Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $6.04M, a 27.12% increase from fiscal 2022.
- Acurx Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $4.75M, a 134.18% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.07M 10-Q · filed 2026-08-13 | $1.41M 10-Q · filed 2026-08-13 | $1.69M derived: sum of 3 quarters · filed 2026-08-13 | $2.12M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $341.47K 10-Q · filed 2026-05-11 | $623.27K derived: sum of 2 quarters · filed 2026-05-11 | $1.05M derived: sum of 3 quarters · filed 2026-05-11 | $1.58M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $281.81K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $711.50K derived: sum of 2 quarters · filed 2026-03-12 | $1.24M derived: sum of 3 quarters · filed 2026-08-13 | $1.83M 10-K · filed 2026-03-12 |
| 2025-09-30 | $429.69K 10-Q · filed 2025-11-12 | $953.90K derived: sum of 2 quarters · filed 2026-08-13 | $1.55M 10-Q · filed 2025-11-12 | $2.38M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $524.21K 10-Q · filed 2026-08-13 | $1.12M 10-Q · filed 2026-08-13 | $1.95M derived: sum of 3 quarters · filed 2026-08-13 | $3.15M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $598.80K 10-Q · filed 2026-05-11 | $1.42M derived: sum of 2 quarters · filed 2026-05-11 | $2.62M derived: sum of 3 quarters · filed 2026-05-11 | $4.45M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $825.06K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.02M derived: sum of 2 quarters · filed 2026-03-12 | $3.85M derived: sum of 3 quarters · filed 2026-03-12 | $5.40M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.20M 10-Q · filed 2025-11-12 | $3.02M derived: sum of 2 quarters · filed 2025-11-12 | $4.58M 10-Q · filed 2025-11-12 | $6.52M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.83M 10-Q · filed 2025-08-11 | $3.38M 10-Q · filed 2025-08-11 | $5.32M derived: sum of 3 quarters · filed 2025-08-11 | $6.67M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $1.56M 10-Q · filed 2025-05-12 | $3.50M derived: sum of 2 quarters · filed 2025-05-12 | $4.85M derived: sum of 3 quarters · filed 2025-05-12 | $6.58M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $3.29M derived: sum of 2 quarters · filed 2025-03-17 | $5.03M derived: sum of 3 quarters · filed 2025-03-17 | $6.04M 10-K · filed 2025-03-17 |
| 2023-09-30 | $1.35M 10-Q · filed 2024-11-12 | $3.09M derived: sum of 2 quarters · filed 2024-11-12 | $4.10M 10-Q · filed 2024-11-12 | $5.53M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.74M 10-Q · filed 2024-08-08 | $2.75M 10-Q · filed 2024-08-08 | $4.18M derived: sum of 3 quarters · filed 2024-08-08 | $5.78M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.02M 10-Q · filed 2024-05-14 | $2.45M derived: sum of 2 quarters · filed 2024-05-14 | $4.04M derived: sum of 3 quarters · filed 2024-05-14 | $4.95M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $3.02M derived: sum of 2 quarters · filed 2024-03-15 | $3.94M derived: sum of 3 quarters · filed 2024-03-15 | $4.75M 10-K · filed 2024-03-15 |
| 2022-09-30 | $1.59M 10-Q · filed 2023-11-13 | $2.50M derived: sum of 2 quarters · filed 2023-11-13 | $3.32M 10-Q · filed 2023-11-13 | $4.04M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $911.69K 10-Q · filed 2023-08-11 | $1.73M 10-Q · filed 2023-08-11 | $2.45M derived: sum of 3 quarters · filed 2023-08-11 | $3.57M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $818.89K 10-Q · filed 2023-05-12 | $1.54M derived: sum of 2 quarters · filed 2023-05-12 | $2.66M derived: sum of 3 quarters · filed 2023-05-12 | $2.76M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $716.22K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.84M derived: sum of 2 quarters · filed 2023-03-15 | $1.94M derived: sum of 3 quarters · filed 2023-03-15 | $2.03M 10-K · filed 2023-03-15 |
| 2021-09-30 | $1.13M 10-Q · filed 2022-11-10 | $1.22M derived: sum of 2 quarters · filed 2022-11-10 | $1.31M 10-Q · filed 2022-11-10 | $1.77M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $95.07K 10-Q · filed 2022-08-12 | $186.98K 10-Q · filed 2022-08-12 | $644.51K derived: sum of 3 quarters · filed 2022-08-12 | $1.30M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $91.91K 10-Q · filed 2022-05-10 | $549.44K derived: sum of 2 quarters · filed 2022-05-10 | $1.21M derived: sum of 3 quarters · filed 2022-05-10 | $1.61M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $457.53K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $1.12M derived: sum of 2 quarters · filed 2022-03-16 | $1.52M derived: sum of 3 quarters · filed 2022-03-16 | $2.20M 10-K · filed 2022-03-16 |
| 2020-09-30 | $659.98K 10-Q · filed 2021-11-12 | $1.06M derived: sum of 2 quarters · filed 2021-11-12 | $1.75M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $400.74K 10-Q · filed 2021-08-13 | $1.09M 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |